Browse the evidence

Discontinuation of obesity pharmacotherapy leads to significant weight regain and recurrence of metabolic benefits loss, necessitating lifelong treatment or intensive lifestyle support.

Obesity is a chronic condition, much like high blood pressure. If you stop your medication, you will likely regain the weight and your health markers (like blood sugar and blood pressure) may worsen. Most people need to stay on treatment long-term to maintain their health benefits. If you want to stop, discuss a plan with your doctor, as weight regain is very common.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior glycemic control and weight loss compared to selective GLP-1 receptor agonists by improving beta-cell function, enhancing insulin sensitivity independent of weight loss, and modulating central appetite regulation.

Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective for lowering blood sugar and reducing body weight, often outperforming older GLP-1 drugs. It improves insulin sensitivity directly, not just through weight loss. Common side effects like nausea may be less severe due to the GIP component. It is prescribed for Type 2 Diabetes and Obesity.

Oral GLP-1 receptor agonists (orforglipron and oral semaglutide) produce clinically meaningful double-digit weight loss (11.2–13.6%) and cardiometabolic improvements in adults with obesity without diabetes, offering a viable alternative to injectable therapies.

Oral GLP-1 medications like orforglipron and oral semaglutide are now proven to help adults with obesity lose significant weight (11-13%) and improve heart health markers without needing injections. If you struggle with needles or prefer a pill, these are viable, effective options, though you should discuss specific dosing rules and potential side effects like nausea with your doctor.

Treatment with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, liraglutide 3.0 mg) or GLP-1/GIP co-agonists (tirzepatide) is recommended for adults with overweight or obesity at moderate or high ASCVD risk to reduce weight and cardiovascular risk factors.

If you have overweight or obesity and are at moderate or high cardiovascular risk, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are recommended treatments that significantly reduce weight and cardiovascular risk factors, often more effectively than lifestyle changes alone.

Semaglutide, a GLP-1 receptor agonist, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity through glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation.

Semaglutide is a prescription medication for T2DM and obesity that works by mimicking a gut hormone to regulate blood sugar, reduce appetite, and slow digestion. It is available as a weekly injection or a daily pill. Clinical trials show significant weight loss (4-15%) and improved blood sugar control (HbA1c reduction of 1.0-1.8%). Common side effects include nausea, which often improves over time. It is recommended for patients with cardiovascular risk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo, other GLP-1 agonists, and insulin.

If you have Type 2 Diabetes, tirzepatide is a highly effective once-weekly injection that lowers blood sugar and helps you lose significant weight, often outperforming other common diabetes medications and insulin. While it can cause temporary stomach issues like nausea, these are usually mild and manageable, and the long-term benefits for your heart, kidneys, and overall metabolic health are substantial.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) significantly reduce body weight and improve glycemic control in patients with Type 2 Diabetes and Obesity.

GLP-1 receptor agonists are highly effective for weight loss and blood sugar control in obesity and Type 2 Diabetes. Options include daily or weekly injections and oral tablets. Expect significant weight loss (15-24% depending on the drug) and improved metabolic health. Discuss specific drug choice (e.g., Semaglutide vs. Tirzepatide) with your doctor based on efficacy needs and administration preference.

Subcutaneous semaglutide 2.4 mg administered once weekly reduces the risk of death from cardiovascular causes by 20% in patients with overweight or obesity without diabetes, based on the SELECT trial.

If you have had a heart attack and are overweight or obese but do not have diabetes, ask your doctor about semaglutide 2.4 mg. It is taken once weekly and has been shown to significantly reduce the risk of dying from heart-related causes. Be aware of potential stomach issues and the high cost if not covered by insurance.

Continuous administration of GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produces significant weight loss (6-22%) and cardiovascular risk reduction, but discontinuation leads to rapid weight regain and loss of therapeutic benefits.

Obesity pharmacotherapy with GLP-1/GIP agonists is highly effective for weight loss and cardiovascular health, but it is not a 'cure' with a fixed end date. You must continue the medication long-term to maintain weight loss; stopping leads to rapid regain. Discuss with your doctor whether the benefits of continuous therapy outweigh the burden of daily/weekly injections and potential side effects.

GLP-1 and dual/triple agonist therapies (semaglutide, tirzepatide, retatrutide) produce double-digit mean weight loss (15-24%) in clinical trials, significantly exceeding older pharmacotherapies.

If you have obesity, newer GLP-1 or dual/triple agonist medications can help you lose 15-20% of your body weight, which is significantly more than older drugs. These are taken as weekly injections (or soon, oral pills). You must discuss insurance coverage and potential side effects like nausea with your doctor, as cost and access are major hurdles.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce substantial weight loss (10-25%) and improve glycemic control through appetite suppression and enhanced satiety.

GLP-1 and GIP/GLP-1 agonists are highly effective for weight loss, achieving 10-25% reduction. They work by suppressing appetite and increasing satiety. Treatment requires a gradual dose increase to manage common gastrointestinal side effects like nausea. These drugs are indicated for adults with obesity or overweight with comorbidities, and should be used alongside lifestyle changes.

At maximum approved doses, tirzepatide (15 mg) produces significantly greater weight loss and glycemic improvement than semaglutide (2.4 mg).

If you are treating obesity with GLP-1/GIP agonists at their maximum FDA-approved doses, Tirzepatide (15 mg) will likely produce more weight loss and better blood sugar control than Semaglutide (2.4 mg). However, cost and availability may make Semaglutide a more practical first choice for some patients.

Modern incretin-based and multi-agonist peptide therapies (GLP-1, GIP/GLP-1, and triple agonists) induce double-digit percentage weight loss (15-25%) that approaches or exceeds outcomes historically associated with bariatric surgery.

If you have obesity, modern peptide therapies like tirzepatide or semaglutide can help you lose 15-25% of your body weight, which is significantly more than older drugs and approaches the results of surgery. These treatments work by targeting the hormones that control your hunger and metabolism. While they are injectable and can be expensive, they are increasingly considered first-line treatments, especially if you have other health risks like heart disease or diabetes. You should discuss these options with your doctor to see if they are appropriate for you.

Semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE) in individuals with overweight or obesity without diabetes, establishing pharmacological weight loss as cardiovascular risk-modifying therapy.

If you have overweight or obesity but no diabetes, semaglutide 2.4 mg can help reduce your risk of serious heart problems like heart attack and stroke. This benefit is independent of your blood sugar levels. It is an injectable medication taken once a week. You should talk to your doctor about whether this is right for you, especially if you have other cardiovascular risk factors.

Semaglutide (2.4 mg weekly) significantly improves MASH resolution and fibrosis in patients with F2-F3 fibrosis, with benefits extending to significant weight loss and metabolic improvements.

If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Semaglutide is a new once-weekly injection option. It significantly reduces liver inflammation and scarring, and also promotes weight loss and improves blood sugar and cholesterol. It is generally well-tolerated, though gastrointestinal side effects are common initially.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.

If you have obesity and cardiovascular risk factors, GLP-1 agonists like semaglutide or liraglutide are highly effective. They help you lose significant weight and reduce your risk of heart attacks and strokes. These are typically injected weekly or daily. Discuss with your doctor if you are a candidate, especially if you have obesity-related complications.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (up to 2.6%) and body weight (up to 12.9 kg) in Type 2 Diabetes patients, outperforming existing GLP-1 agonists and insulin.

Tirzepatide is a once-weekly injectable medication for Type 2 Diabetes that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective at lowering blood sugar and promoting significant weight loss, often outperforming other common diabetes medications. Patients should expect a gradual dose increase to minimize stomach upset, and pharmacists play a key role in managing side effects and ensuring adherence.

Long-term use of GLP-1 receptor agonists (GLP-1 RAs) provides durable cardiovascular and metabolic protection without significant long-term adverse events, whereas discontinuation leads to rapid weight regain and reversal of cardioprotective benefits.

Treat obesity as a chronic condition requiring long-term management with GLP-1 RAs. Do not stop the medication once you reach your goal weight, as you will likely regain the weight and lose cardiovascular benefits. Expect gastrointestinal side effects early on, but know they usually improve after a few months. Work with your doctor to manage costs and side effects to maintain adherence.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual agonists (tirzepatide) are highly effective for weight loss and cardiovascular risk reduction in adults with obesity.

If lifestyle changes alone haven't worked, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are injectable drugs that mimic hormones to reduce hunger and improve metabolism. They have been shown to produce significant weight loss (14-20%) and improve heart health markers.

New-generation incretin-based obesity medications (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) achieve mean weight loss exceeding 10-15%, which is two- to three-fold greater than previous obesity medications.

If you have obesity, new medications like semaglutide (2.4 mg weekly) or tirzepatide (5-15 mg weekly) can help you lose 15% or more of your body weight, which is significantly more than older drugs. These are taken as weekly injections. Because obesity is a chronic condition, you likely need to stay on these medications long-term to maintain the weight loss, similar to how you manage blood pressure or diabetes with daily meds.

GLP-1 receptor agonists (semaglutide, tirzepatide) provide significant cardiovascular benefits, including a 20% reduction in major adverse cardiovascular events (MACE) in patients with obesity and pre-existing cardiovascular disease but without diabetes.

If you have obesity and existing heart disease, even without diabetes, taking semaglutide (2.4 mg weekly) can significantly lower your risk of heart attack, stroke, or cardiovascular death by about 20%. This benefit appears to come from the drug's direct effects on the body, not just from losing weight.

Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity compared to placebo and other active comparators.

Tirzepatide is a once-weekly injection that helps your body manage blood sugar and lose weight more effectively than many existing treatments. It works by mimicking hormones that regulate appetite and insulin. You start with a low dose to minimize stomach upset and gradually increase it. It is approved for both type 2 diabetes and obesity management.

Modern GLP-1 receptor agonists (e.g., liraglutide) and combination therapies (e.g., phentermine/topiramate) offer significant, sustained weight loss with improved safety profiles compared to historical agents.

Modern obesity treatments like GLP-1 agonists (e.g., liraglutide) and combination therapies (e.g., phentermine/topiramate) are effective and safer than older drugs. They require medical supervision and are prescribed for specific patient profiles.

GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide 15 mg) produce significant weight loss (15–21%) and improve obesity-related comorbidities, but discontinuation leads to substantial weight regain, necessitating long-term maintenance therapy.

Use FDA-approved GLP-1 or dual agonists for significant obesity. These drugs work by mimicking gut hormones to reduce appetite and increase satiety. You must take them long-term; stopping leads to weight regain. Discuss titration schedules with your doctor to manage side effects like nausea.